Cushing has neven been operating below 25-26% of working capacity. When it approached this apparently critical level, efforts were made to raise reserves way above this magical level. This should tell you something important about Cushing.
Now it sits JUST above at this level (20/76.6=0,261). If inventories are not restored swiftly, what happens then? We’ll see
I think $NKTR drops again on Monday, because SURELY some people were holding NKTR purely on the bet that ABBV would buy it. However, AbbVie placed the opposite bet to Nektar's thesis (new MoA, etc), so...
This is probably a local bottom for Nektar: worst sentiment + no big catalysts for ~2 years.
That said, there are actually two decent catalysts before then:
-- The lawsuit in late Aug–early Sep; hopefully it puts the issue to bed
-- The REZOLVE-AD off-treatment readout in January-ish 2027. Rezpeg finally gets to show its single most important feature
> But that’s where the opportunity is, novel moa, durability and safety for 2L use.
A counterpoint: Nektar designed its trials as if it's 1L (only JAK-naive, biologics-naive). The management has to explicitly show a differentiation in demographics. What if rezpeg and dupi overlap a great deal? NKTR is dead, then.
I'm almost sure that's what market thinks about NKTR, and it explains the price action we've been seeing so far.